Publications

Johanna Olweus:

Bartok O, Pataskar A, Nagel R, Laos M, Goldfarb E, Hayoun D, Levy R, Körner PR, Kreuger IZM, Champagne J, Zaal EA, Bleijerveld OB, Huang X, Kenski J, Wargo J, Brandis A, Levin Y, Mizrahi O, Alon M, Lebon S, Yang W, Nielsen MM, Stern-Ginossar N, Altelaar M, Berkers CR et al. (2020)
Anti-tumour immunity induces aberrant peptide presentation in melanoma
Nature
DOI 10.1038/s41586-020-03054-1, PubMed 33328638

Ali M, Foldvari Z, Giannakopoulou E, Böschen ML, Strønen E, Yang W, Toebes M, Schubert B, Kohlbacher O, Schumacher TN, Olweus J (2019)
Induction of neoantigen-reactive T cells from healthy donors
Nat Protoc, 14 (6), 1926-1943
DOI 10.1038/s41596-019-0170-6, PubMed 31101906

Olweus J, Lund-Johansen F (2019)
Finding Neo (antigens, that is)
Blood, 134 (2), 108-109
DOI 10.1182/blood.2019001334, PubMed 31296544

Karl-Johan Malmberg

Goldenson BH, Zhu H, Wang YM, Heragu N, Bernareggi D, Ruiz-Cisneros A, Bahena A, Ask EH, Hoel HJ, Malmberg KJ, Kaufman DS (2020)
Umbilical Cord Blood and iPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles
Front Immunol, 11, 561553
DOI 10.3389/fimmu.2020.561553, PubMed 33178188

Lachota M, Vincenti M, Winiarska M, Boye K, Zagożdżon R, Malmberg KJ (2020)
Prospects for NK Cell Therapy of Sarcoma
Cancers (Basel), 12 (12)
DOI 10.3390/cancers12123719, PubMed 33322371

Tschan-Plessl A, Kalberer CP, Wieboldt R, Stern M, Siegler U, Wodnar-Filipowicz A, Gerull S, Halter J, Heim D, Tichelli A, Tsakiris DA, Malmberg KJ, Passweg JR, Bottos A (2020)
Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma
Cytotherapy (in press)
DOI 10.1016/j.jcyt.2020.09.009, PubMed 33268029

Zhu H, Blum RH, Bernareggi D, Ask EH, Wu Z, Hoel HJ, Meng Z, Wu C, Guan KL, Malmberg KJ, Kaufman DS (2020)
Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity
Cell Stem Cell, 27 (2), 224-237.e6
DOI 10.1016/j.stem.2020.05.008, PubMed 32531207

Enqvist M, Jacobs B, Junlén HR, Schaffer M, Melén CM, Friberg D, Wahlin BE, Malmberg KJ (2019)
Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma
Front Immunol, 10, 2085
DOI 10.3389/fimmu.2019.02085, PubMed 31572357

Jon Amund Kyte

Kyte JA, Andresen NK, Russnes HG, Fretland SØ, Falk RS, Lingjærde OC, Naume B (2020)
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J Transl Med, 18 (1), 269
DOI 10.1186/s12967-020-02421-w, PubMed 32620163

Kyte JA, Røssevold A, Falk RS, Naume B (2020)
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
J Transl Med, 18 (1), 252
DOI 10.1186/s12967-020-02424-7, PubMed 32576225

Casey NP, Kyte JA, Fujiwara H (2020)
Use of RNA Interference with TCR Transfer to Enhance Safety and Efficiency
Methods Mol Biol, 2115, 327-349
DOI 10.1007/978-1-0716-0290-4_18, PubMed 32006409

Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred Ø, OSBREAC, Frigessi A, Sahlberg KK, Sørlie T, Russnes HG, Naume B, Kristensen VN (2019)
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750